Home > Haematology > ASH 2021 > Acute Myeloid Leukaemia > Benefits of eprenetapopt plus azacytidine for TP53-mutant MDS and oligoblastic AML

Benefits of eprenetapopt plus azacytidine for TP53-mutant MDS and oligoblastic AML

Presented By
Dr David Sallman, H. Lee Moffitt Cancer Center, FL, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASH 2021
Trial
Phase 2
The combination therapy of eprenetapopt plus azacytidine showed favourable efficacy and safety in patients with TP53-mutant myelodysplastic syndrome (MDS) and oligoblastic acute myeloid leukaemia (AML). The high-risk subpopulation of patients with biallelic TP53 mutations or complex karyotype at baseline had higher complete response rates than patients who do not display these features [1]. Dr David Sallman (H. Lee Moffitt Cancer Center, FL, USA) explained that the impact of TP53 mutations in MDS is large. “TP53 mutations occur in up to 20% of the patients with MDS and AML, resulting in inferior overall survival (OS) outcomes. The current therapies for this population are insufficient.” The combination regimen of eprenetapopt, a first-in-class p53 reactivator, plus azacytidine was evaluated in 2 phase 2 trials (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on